Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia: Complete Statistical AnalysisIndependent statistical analysis of Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00901342).
- Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open Label Study Telmisartan and Amlodipine in Hypertension: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study Telmisartan and Amlodipine in Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00614380).
- Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia: primary endpoint results, effect estimate with…
- Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients: Complete Statistical AnalysisIndependent statistical analysis of Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen: Complete Statistical AnalysisIndependent statistical analysis of Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease: Complete Statistical AnalysisIndependent statistical analysis of Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact: Complete Statistical AnalysisIndependent statistical analysis of Open Multi-cohort Study of the First Phase of Safety of a Drug Based on Double Recombinant Vaccinia Virus VV-GMCSF-Lact: primary endpoint results, effect estimate with confidence interval, sample-size…
- Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Open-label Extension for Phase 3 Clinical Trials of Simufilam: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension for Phase 3 Clinical Trials of Simufilam: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05575076).
- Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension of the Dose Finding Study (DSC/08/2357/36) in Patients With Poly Juvenile Idiopathic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05459688).
- Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Open-Label Extension Study of Trofinetide for Rett Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Study of Trofinetide for Rett Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04776746).
- Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD): primary endpoint results, effect estimate with confidence interval, sample-size…
- Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study: Complete Statistical AnalysisIndependent statistical analysis of Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study: primary endpoint results, effect estimate with confidence interval,…
- Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: Complete Statistical AnalysisIndependent statistical analysis of Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety and Tolerability of Oxymorphone IR and ER in Opioid Tolerant Pediatric Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety and Tolerability Study of Oxymorphone for Acute Postoperative Pain in Pediatric Subjects.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212: Complete Statistical AnalysisIndependent statistical analysis of Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults: Complete Statistical AnalysisIndependent statistical analysis of Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults: primary endpoint results, effect estimate with…
- Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE): Complete Statistical AnalysisIndependent statistical analysis of Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04634669).
- Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD): Complete Statistical AnalysisIndependent statistical analysis of Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05030350).
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02904902).
- Open-label Study of ASP2151 in Herpes Simplex Patients: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of ASP2151 in Herpes Simplex Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02209324).
- Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) – Tuberculosis (TB) Co-infection: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Open-label Study of Dupilumab in Patients With Atopic Dermatitis: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Dupilumab in Patients With Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01949311).
- Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Levetiracetam Intravenous Infusion in Children (1 Month-4 Years Old) With Epilepsy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-Label Study of OTO-201 for Treatment of AOMT: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of OTO-201 for Treatment of AOMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02408796).
- Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study of Parsaclisib, in Japanese Participants With Relapsed or Refractory Follicular Lymphoma (CITADEL-213): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Open-label Study of Safety and Tolerability of Memantine in Children With Autism: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Safety and Tolerability of Memantine in Children With Autism: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A: primary endpoint results, effect estimate with…
- Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism: Complete Statistical AnalysisIndependent statistical analysis of Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism: primary endpoint results, effect estimate…
- Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219: Complete Statistical AnalysisIndependent statistical analysis of Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…